Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Cartier Silver Outlines an 800m by 500m Epithermal Silver Polymetallic Target on Gonalbert Property, Potosi Department, Southern Bolivia (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Arch Biopartners Inc. V.ARCH

Alternate Symbol(s):  ACHFF

Healthcare Biotechnology
Arch Biopartners Inc is a clinical stage company developing technologies with the potential to make medical or commercial impacts. The company is developing a drug platform Metablok to produce drug candidates to inhibit organ inflammation caused via the DPEP-1 pathway. Its under development portfolio is AB569, a potential new treatment for antibiotic resistant bacterial infections in the lungs or wounds; and, Borg peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (TSXV:ARCH)

Fundamentals Snapshot (TSXV:ARCH)

Current News (TSXV:ARCH)

Arch Biopartners Announces Positive Results of Dose Escalation Human Trial for LSALT Peptide

GlobeNewswire April 18, 2023

Arch Biopartners Receives Funding for Development of LSALT Peptide Drug Program

GlobeNewswire March 23, 2023

Arch Scientist Awarded CIHR Grant to Study the Role of Dipeptidase-1 in Chronic Kidney Disease

GlobeNewswire February 7, 2023

Shares for Interest Debt Settlement; Grants Options

GlobeNewswire December 15, 2022

Arch Biopartners (TSXV:ARCH) welcomes Farris Smith as a Strategic Advisor

Brieanna McCutcheon  October 5, 2022

Arch Biopartners Adds Farris Smith as a Strategic Advisor

GlobeNewswire October 5, 2022

Arch Biopartners Adds Dr. David Luke as a Strategic Advisor, Clinical Trials

GlobeNewswire August 5, 2022

Arch Biopartners' (TSXV:ARCH) trial receives approval to include LSALT Peptide

Caroline Egan  February 14, 2022

Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)

GlobeNewswire February 14, 2022
View More News ››

Opinion & Analysis (TSXV:ARCH)

No current opinion is available.
View More Opinion ››

Bullboard Posts (TSXV:ARCH)

How Low Will It Go

I started position this week and have added to position each day. We continue to hit new 52 week lows daily. I just cannot understand...
Viking2233 - 12 days ago

Buying Action

Some nice buying action final 30 minutes, looks lije someone trying accumulate at house 83. Also two large 50k bids moving up and been...
Viking2233 - May 24, 2023

Shorting Action

Does anyone have any explanation for the daily shorting on this stock for the past 6 months? The 1 year chart is ugly st best, the...
Viking2233 - May 23, 2023

RE:Analysis

I agree, it’s crucial to acknowledge the concerns raised by investors regarding the delay publishing the Phase 2 data. The lack of...
Cb27743 - May 22, 2023

Analysis

Hello, I have been looking into this company and its potential upside. There are numerous positive aspects such as successful trials...
Viking2233 - May 21, 2023

Reuters - Arch Biopartners

 Nice coverage by Reuters this morning:   * ARCH BIOPARTNERS ANNOUNCES POSITIVE RESULTS OF DOSE ESCALATION HUMAN TRIAL FOR...
Riverfolk - April 18, 2023
View more Bullboard ››

Tantalex Lithium Resources Corp

Tantalex Lithium Resources Corp

Tantalex Lithium Resources Corp is a mining exploration and development company. It is engaged in the acquisition ...
View More »